DIABETES
The HA-8190V analyser, which has been designed to support clinical workflow.
months ago, with ARKRAY now able to market and support its products directly to customers.
While POCT is an important aspect of
ARKRAY business, the priority has to be improving diabetes testing in the NHS hospital laboratory with the HA-8190V analyser, which has been designed to support clinical workflow. ARKRAY’s latest glycohaemoglobin (HbA1c) analyser is based on HPLC technology and can run in dual modes. A recent official evaluation study10
showed its excellent total
In the UK, the drive to identify these people has gained momentum in the post-COVID aftermath, placing increased pressure on diabetes testing services, both in the community and in the hospital laboratory. Innovative solutions are required in the face of already overstretched resources. With guidelines9
recommending
testing every three to six months, laboratories must have access to technology that can speed up results delivery without increasing the risk of false negatives and putting patients at risk of side effects.
Point-of-care HbA1c results in 90 seconds ARKRAY has two high-speed HbA1c solutions, both suitable for diagnosis and screening. Let’s look first at the value of offering rapid point-of-care testing (POCT) in community clinics. ARKRAY’s The Lab 001 is the only POCT analyser that can be used for both screening and diagnosis. It provides laboratory equivalent HbA1c results in 90 seconds from a fingerprick of blood. The electropherogram generated indicates the HbA1c value along with any clinically significant variants so that accurate results can be obtained even in the presence of raised HbF, sickle cell anaemia, or other clinically significant variants. Offering this type of diagnostic accuracy at speed dramatically reduces patient wait time to find out their results. In turn, it also aids community healthcare professionals in the early detection of
patients with variants and the ongoing monitoring and treating of patients with harder to control conditions.
Company heritage
The Japanese company has been a global leader in diabetes solutions for more than 60 years. In 1979, it developed the first high-performance liquid chromatography (HPLC) HbA1c fractionation analyser (the HA-8110) suitable for quantitative analysis in the clinical laboratory. In the UK and mainland Europe, however, its technologically advanced products had previously only been available through a distributor. This ended just over six
reproducibility, with coefficient of variation (CV) consistently less than 1%. The system detects and separates variant haemoglobin automatically, seamlessly switching between its FAST and Variant modes. Around 80% of samples can then be routinely assessed within 24 seconds. The software matches the sample against prior results and only if it flags up inconsistencies will it be automatically routed to the Variant mode, which itself only takes 58 seconds for more in-depth analysis. Some competitor systems claim this feature but staff have to be available to stop, change reagents and restart the system to switch between modes. With the HA-8190V analyser, no-one has to intervene, nothing is done manually, the system does it automatically.
Overall, the HA-8190V can process samples at almost twice the speed of its competitors. If a laboratory is required to run between 200 and 400 samples a day, this presents significant quantifiable time savings, which will directly benefit workflow and test turnaround times
Designed for NHS networks The product was only launched in Europe in 2021 and like its predecessor, the
The HA-8190V analyser in operation.
WWW.PATHOLOGYINPRACTICE.COM SEPTEMBER 2022 43
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64
